ResMed Earnings Preview: What to Expect

Core Insights - ResMed Inc. is a medical device and software company focused on respiratory disorders, valued at $32.1 billion, with Q3 2026 earnings expected soon [1] Financial Performance - Analysts anticipate ResMed's Q3 2026 EPS to be $2.77, reflecting a 16.9% increase from $2.37 in the same quarter last year [2] - For fiscal 2026, the projected EPS is $10.98, up 15% from $9.55 in fiscal 2025, with an expected rise to $11.98 in fiscal 2027, representing a 9.1% year-over-year increase [3] Stock Performance - ResMed's stock has seen a marginal decline over the past 52 weeks, underperforming the S&P 500 Index's 11.9% rise but slightly outperforming the State Street Healthcare Select Sector SPDR ETF's 1.2% decline [3] - Following the release of Q2 2026 earnings, the stock declined marginally despite revenue growth of 11% year-over-year to $1.4 billion and adjusted EPS of $2.81, which exceeded Wall Street estimates [4] Analyst Ratings - The overall rating for ResMed's stock is "Moderate Buy," with 19 analysts covering it: 8 recommend "Strong Buy," 2 "Moderate Buy," 8 "Hold," and 1 "Strong Sell" [5] - The average analyst price target for ResMed is $295.23, indicating a potential upside of 33.9% from current levels [5]